DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

STRONG Program for Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Gastrointestinal Cancer

Interventions: Behavioral: Consultations with Moffitt Dietician
Behavioral: Daily Food Intake Diary with Fitbit smartphone application
Behavioral: Questionnaires

First Posted Date: 2022-12-14

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 10

Registration Number: NCT05649969

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

Not Applicable

Active, not recruiting

Conditions: Smoking Cessation
Cervical Cancer
High Grade Cervical Dysplasia

Interventions: Behavioral: Smoking Cessation treatment delivered by Tobacco Free Florida Quitline
Drug: Nicotine Lozenge
Drug: Nicotine patch
Behavioral: Motivation and Problem Solving (MAPS) intervention

First Posted Date: 2022-12-09

Last Posted Date: 2025-03-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 360

Registration Number: NCT05645146

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1

Recruiting

Conditions: Unresectable Melanoma
Non-Cutaneous Melanoma
Metastatic Melanoma
Ocular Melanoma
Iris Melanoma
Acral Melanoma
Uveal Melanoma
Mucosal Melanoma
Cutaneous Melanoma
Conjunctival Melanoma

Interventions: Biological: TBio-4101
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2

First Posted Date: 2022-11-29

Last Posted Date: 2025-02-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT05628883

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Active, not recruiting

Conditions: Renal Cell Carcinoma Stage IV

Interventions: Other: mHealth Smart Phone Application
Behavioral: eHEALS digital literacy test
Behavioral: Weekly Quiz
Behavioral: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
Behavioral: Patient Post Intervention Survey

First Posted Date: 2022-10-14

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05579847

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
Drug: Calaspargase Pegol
Drug: Rituximab

First Posted Date: 2022-10-14

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05581030

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Vyxeos
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2022-09-28

Last Posted Date: 2025-02-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT05558124

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Radiation: Genomically Guided Radiation Therapy

First Posted Date: 2022-09-06

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 86

Registration Number: NCT05528133

Locations: 🇺🇸
Morton Plant Hospital - Baycare Health System, Clearwater, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2

Recruiting

Conditions: Penile Carcinoma

Interventions: Drug: Dostarlimab
Drug: Niraparib

First Posted Date: 2022-09-02

Last Posted Date: 2025-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT05526989

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase 2

Recruiting

Conditions: Uveal Melanoma
Ocular Melanoma

Interventions: Drug: Pembrolizumab
Drug: Olaparib

First Posted Date: 2022-09-01

Last Posted Date: 2025-03-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 37

Registration Number: NCT05524935

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
HER2-negative Breast Cancer

Interventions: Biological: HER2 - primed Dendritic cells
Biological: HER3 - primed Dendritic cells

First Posted Date: 2022-08-17

Last Posted Date: 2025-03-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT05504707

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy